(Originally published at WEIXIN https://mp.weixin.qq.com/s?__biz=Mzg5NzcxMjUzOQ==&mid=2247489766&idx=1&sn=43ccdc4538f4ebed25b74f301a0e8736&scene=21&poc_token=HJtPzmmjahdcdqaZ57VU4nBndxKzZwlS3QrelgNS)

March 27, 2026, GEM listed companies Ningbo David Medical Device Co., Ltd ( Securities code: 300314 Securities abbreviation: David Medical )Release Announcement on a wholly-owned subsidiary involving a major lawsuit 》.

The announcement shows that David Medical and its wholly owned subsidiaries Ningbo Verkaidi Medical Device Co, Ltd (abbreviated as “Vilkedi”) is a defendant in two patent infringement cases.

The lawsuit began in May 2025, and the plaintiff is a globally renowned healthcare group Johnson & Johnson (Johnson & Johnson) Its high-end medical Core companies in the field of surgical devices—— Silag International Ltd (Abbreviation“ Silag ”), headquartered in Schaffhausen, Switzerland, with core business focus Research, development, production and global sales of surgical instruments , In particular, it has profound technical accumulation and patent layout in sub-sectors such as ultrasonic surgical instruments, electric cutting and suturing instruments, surgical staple cartridges, and power-controlled surgical instruments.

May 20, 2025 and July 7, 2025, Vilcaidi Receive Nanjing Intermediate People's Court of Jiangsu Province Regarding the relevant legal documents served ((2025) Su01 Minchu No. 1355, (2025) Su01 Minchu No. 1356, (2025) Su01 Minchu No. 1836), Silag filed a lawsuit with the Nanjing Intermediate People's Court of Jiangsu Province on the grounds that Vilkaidi infringed his invention patent rights. The litigation amounts in the three cases are 5 million yuan 、 5 million yuan 、 1 million yuan The Committee recommends that the State party take all necessary measures to ensure that all children, regardless of their age, have access to adequate health care and adequate housing.

Silag Claiming that the defendant's manufactured and sold electric laparoscopic stapler products (D/T/VD/VT series), laparoscopic stapler assembly (staple cartridge) products (including but not limited to the D/T/DA/TA/VD/VT/S/G/DM/TM series, etc.) violated its Chinese invention patents “motor-driven surgical cutting instrument with electric actuator directional control assembly” (Patent No. 201080059401.4), “surgical instrument with power control circuit” (Patent No. 201180057826.6), “nail cartridge for forming nails with different forming nail heights” (Patent No. 200610126469.5).

However, in a recent trial, the plaintiff Silag The litigation request has been changed, and the litigation amounts in cases (2025) Su 01 Minchu No. 1355 and (2025) Su 01 Minchu No. 1356 have been increased to 80.63 million yuan 、 80.63 million yuan , the plaintiff in Case (2025) Su 01 Minchu No. 1836 has withdrawn the lawsuit. So far, the total amount of economic loss compensation claimed by the plaintiff is RMB 161.26 million (161 million yuan).

After investigation, it was found that the patent withdrawn by Sirag was because on January 19 this year, Jiangsu Fenghe Medical Device Co., Ltd., another high-end medical and surgical device manufacturer in China, successfully invalidated it through an invalidity challenge. Patent Office records show that only for this patent, Since 2020, Fenghe Medical has filed at least four invalidity declaration requests, and the National Intellectual Property Administration has made a total of four invalidity decisions. It was not until January this year, after maintaining its validity several times, that the patent was officially declared invalid.

In fact, if we analyze in depth the situation where Silag's patents in China were challenged for invalidity, we will find that more domestic medical and surgical device companies have been involved, indicating that Silag's rights protection has been fully launched in China. Among them, in addition to the two enterprises mentioned above, there are With Nokon Medical Technology (Suzhou) Co., Ltd Baoma Medical Technology (Wuxi) Co., Ltd Suzhou Meidong Huicheng Precision Parts Co., Ltd et al. launched an invalidity challenge to Silag's patent. A total of 23 invalidation cases have been involved, of which 11 have been filed by Fenghe Medical alone.

Among them, Silag mainly participates in the protection of rights involving a number of core invention patents (such as ZL200680035337X, ZL2010800594014, ZL2011800578266, etc.), The technical characteristics are concentrated in core areas such as electric actuator control, ultrasonic energy application, surgical instrument power control, and nail cartridge precision forming. The number of times they are challenged and ineffective is about 3-5 times.

It is not difficult to find that Silag's rights protection goals this time are very clear, all pointing to China's mid-to-high-end surgical device manufacturers, focusing on the core track of domestic substitution. For example, high-end ultrasonic surgical instruments, electric cutting and suturing instruments, precision surgical staple silos, etc., these fields have long been monopolized by foreign-funded enterprises such as Johnson & Johnson and Silag. In recent years, Chinese companies have increased their R&D investment to achieve technological breakthroughs, gradually realized import substitution, and become Silag's main market competitors.

With Sirag's rights protection, China's high-end surgical device industry has been further accelerated to enter the “patent competition era” ahead of schedule, making the originally simple Competition in product prices and channels has been further upgraded to dual competition in technology patents + product markets, which is also conducive to Promote Chinese local enterprises to pay more attention to patents and innovation, and promote the overall direction of the industry Standardized and high-quality development.

In the future, only those original local companies that truly focus on research and development, devote themselves to planning patent layout, do a good job in long-term planning and circumvent design can break through foreign patent barriers through continuous innovation and technological iteration, and truly achieve independent control and domestic substitution of high-end surgical instruments.